Molecular stratification of MDS patients by TP53 mutation status has shown decreased survival in patients harboring a TP53 mutant clone (5), indicating that this is a critical prognostic marker that is also predictive for potential benefit from lenalidomide treatment. This evidence concerns the gene TP53 and myelodysplastic syndrome.